TONSIL PRIMER
Yun Hee Lee, MD1, Seok Goo Cho, MD, PhD2, Seung Eun Jung, MD, PhD3, Sung Hoon Kim, MD, PhD4, Joo
Hyun O, MD, PhD4, Gyeong Sin Park, MD, PhD5, Suk Woo Yang, MD, PhD6, In Seok Lee, MD, PhD7, Chin
Kook Rhee, MD, PhD7, Byung Ock Choi, MD, PhD8
1
Department of Radiation Oncology, Gyeongsang National University Hospital, Gyeongsang National University
2 3 4 5
School of Medicine, Jinju; Departments of Hematology, Radiology, Nuclear Medicine, Pathology,
6 7 8
Ophthalmology, Internal Medicine, and Radiation Oncology, Catholic University Lymphoma Group (CULG),
Seoul St. Mary's Hospital, College of Medicine,
The Catholic University of Korea, Seoul, Korea
Tujuan: Meskipun setiap sub-situs cincin Waldeyer dianggap sebagai faktor prognostik
independen, beberapa penelitian telah menilai prognosis dan pengobatan limfoma tonsil. Hasil
pengobatan dianalisis pada pasien dengan limfoma tonsil primer yang diobati dengan kemoterapi
dan radioterapi (RT).
Bahan dan Metode: Sembilan belas pasien dengan limfoma sel B besar difus dievaluasi, dengan
median follow-up 53 bulan. Usia, jenis kelamin, dan histologi, di antara faktor-faktor lain,
ditinjau. Angka kelangsungan hidup bebas perkembangan (PFS) dan tingkat kelangsungan hidup
keseluruhan (OS) dianalisis.
Hasil: Kebanyakan pasien masuk dalam tahap I-II (94,7) menurut Ann bhor, IPI skor 0 (89,5),
dan remisi lengkap setelah kemoterapi (89,5). Tingkat 5-tahun PFS dan OS adalah 74,6 % dan
80%. Dalam analisis univariat, rituximab, cyclophosphamide, doxorubicin, vincristine, dan
prednisone (R-CHOP) rejimen menghasilkan PFS yang lebih baik daripada rejimen
siklofosfamid, doxorubicin, vincristine, dan prednisone (CHOP) (88.9% vs 50.0; p = 0.053 ).
Dosis RT terkait dengan hasil kelangsungan hidup (p = 0,010 untuk PFS, p = 0,044 untuk OS).
Pasien diklasifikasikan ke dalam kelompok CHOP + RT (> 40 Gy) dan kelompok R-CHOP + RT
(≤40 Gy). Suku bunga PFS 5 tahun adalah 50% dalam kelompok CHOP + RT, dan 100 dalam
kelompok R-CHOP + RT (p = 0,018). Tingkat OS 5 tahun adalah 66,7% dan 100, masing-
masing (p = 0,087).
Kesimpulan: Pasien limfoma tonsil primer biasanya memiliki hasil yang menguntungkan.
Kemoterapi (R-CHOP) dikombinasikan dengan konsolidasi RT dosis rendah yang relatif lebih
aman dan efektif untuk limfoma tonsil primer.
KONFLIK KEPENTINGAN
DAFTAR PUSTAKA remission after anthracycline-containing
chemotherapy. Leuk Lymphoma
1. Lee SJ, Suh CW, Lee SI, et al. Clinical
2013;54:62-8.
characteristics, pathological
6. Miller TP, Dahlberg S, Cassady JR, et al.
distribution, and prognostic factors in
Chemotherapy alone compared with
non- Hodgkin lymphoma of Waldeyer’s
chemotherapy plus radiotherapy for
ring: nationwide Korean study. Korean J
localized intermediate- and high-grade non-
Intern Med 2014;29:352-60.
Hodgkin’s lymphoma. N Engl J Med
2. Qin Y, Shi YK, He XH, et al. Clinical
1998;339:21-6.
features of 89 patients with primary non-
7. Horning SJ, Weller E, Kim K, et al.
Hodgkin’s lymphoma of the tonsil. Ai
Chemotherapy with or without
Zheng 2006;25:481-5.
radiotherapy in limited-stage diffuse
3. Lopez-Guillermo A, Colomo L, Jimenez M,
aggressive non- Hodgkin’s lymphoma:
et al. Diffuse large B-cell lymphoma:
Eastern Cooperative Oncology Group study
clinical and biological characterization and
1484. J Clin Oncol 2004;22:3032-8.
outcome according to the nodal or
8. dos Santos LV, Lima JP, Lima CS, Sasse
extranodal primary origin. J Clin Oncol
EC, Sasse AD. Is there a role for
2005;23:2797-804.
consolidative radiotherapy in the treatment
4. Yahalom J, Illidge T, Specht L, et al.
of aggressive and localized non-
Modern radiation therapy for extranodal
Hodgkin lymphoma? A systematic
lymphomas: field and dose guidelines
review with meta-analysis. BMC
from the International Lymphoma
Cancer 2012;12:288.
Radiation Oncology Group. Int J Radiat
9. Bonnet C, Fillet G, Mounier N, et al. CHOP
Oncol Biol Phys 2015;92:11-31.
alone compared with CHOP plus
5. Chang DT, Mendenhall NP, Lynch JW,
radiotherapy for localized aggressive
Morris CG, Olivier KR. Long-term
lymphoma in elderly patients: a study by the
outcomes for stage I-II aggressive non-
Groupe d’Etude des Lymphomes de
Hodgkin lymphoma of Waldeyer’s ring. Am
l’Adulte. J Clin Oncol 2007;25:787-92.
J Clin Oncol 2009;32:233-7. patients with
10. Persky DO, Unger JM, Spier CM, et al.
early-stage diffuse large B-cell
Phase II study of rituximab plus three
lymphoma of Waldeyer’s ring in
cycles of CHOP and involved-field
radiotherapy for patients with limited-stage Ann Hematol 2005;84:223-6.
aggressive B-cell lymphoma: Southwest 14. Mohammadianpanah M, Daneshbod Y,
Oncology Group study 0014. J Clin Oncol Ramzi M, et al. Primary tonsillar
2008;26:2258-63. lymphomas according to the new World
11. Phan J, Mazloom A, Medeiros LJ, et al. Health Organization classification: to
Benefit of consolidative radiation therapy report 87 cases and literature review and
in patients with diffuse large B-cell analysis. Ann Hematol 2010;89:993-
lymphoma treated with R-CHOP 1001.
chemotherapy. J Clin Oncol 2010;28:4170- 15. Coiffier B, Lepage E, Briere J, et al. CHOP
6. chemotherapy plus rituximab compared
12. Laskar S, Bahl G, Muckaden MA, et al. with CHOP alone in elderly patients with
Primary diffuse large B-cell lymphoma of diffuse large-B-cell lymphoma. N Engl J
the tonsil. Is a higher radiotherapy dose Med 2002;346:235- 42.
required? Cancer 2007;110:816-23. 16. Lowry L, Smith P, Qian W, et al. Reduced
13. Mohammadianpanah M, Omidvai S, dose radiotherapy for local control in non-
Mosalei A, Ahmadloo N. Treatment results Hodgkin lymphoma: a randomised phase
of tonsillar lymphoma: a 10-year experience. III trial. Radiother Oncol 2011;100:86-92.
lymphoma: Southwest Oncology Group 20. Mohammadianpanah M, Daneshbod Y,
study 0014. J Clin Oncol 2008;26:2258-63. Ramzi M, et al. Primary tonsillar
lymphomas according to the new World
17. Phan J, Mazloom A, Medeiros LJ, et al.
Health Organization classification: to
Benefit of consolidative radiation therapy
report 87 cases and literature review and
in patients with diffuse large B-cell
analysis. Ann Hematol 2010;89:993-
lymphoma treated with R-CHOP
1001.
chemotherapy. J Clin Oncol 2010;28:4170-
21. Coiffier B, Lepage E, Briere J, et al. CHOP
6.
chemotherapy plus rituximab compared
18. Laskar S, Bahl G, Muckaden MA, et al.
with CHOP alone in elderly patients with
Primary diffuse large B-cell lymphoma of
diffuse large-B-cell lymphoma. N Engl J
the tonsil. Is a higher radiotherapy dose
Med 2002;346:235- 42.
required? Cancer 2007;110:816-23.
22. Lowry L, Smith P, Qian W, et al. Reduced
19. Mohammadianpanah M, Omidvai S,
dose radiotherapy for local control in non-
Mosalei A, Ahmadloo N. Treatment results
Hodgkin lymphoma: a randomised phase
of tonsillar lymphoma: a 10-year experience.
III trial. Radiother Oncol 2011;100:86-92.
Ann Hematol 2005;84:223-6.